A systematic review of cannabidiol dosing in clinical populations
British Journal of Clinical Pharmacology2019Vol. 85(9), pp. 1888–1900
Citations Over TimeTop 1% of 2019 papers
Sophie Millar, Nicole L. Stone, Z.D. Bellman, Andrew Yates, Timothy J. England, Saoirse E. O’Sullivan
Abstract
This review highlights that CBD has a potential wide range of activity in several pathologies. Pharmacokinetic studies as well as conclusive phase III trials to elucidate effective plasma concentrations within medical contexts are severely lacking and highly encouraged.
Related Papers
- → Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis(2010)189 cited
- → An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives(2023)43 cited
- → Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol(2016)70 cited
- → Theoretical calculation of some chemical properties of the cannabidiol (CBD) molecule(2021)4 cited
- → Constituents of Cannabis Sativa L. II: Absence of Cannabidiol in an African Variant(1973)61 cited